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ABSTRACT
Glucagonoma is a rare and slow-growing pancreatic tumor that usually manifests as glucagonoma syndrome. It is mainly 
characterized by a typical Dermatosis named necrolytic migratory erythema (NME), Diabetes and glucagon oversecretion. 
Deep vein thrombosis and Depression complete this set. We report the case of an advanced glucagonoma with liver spread, 
where all these 4D symptoms occurred but a chronic secretory Diarrhea was the most relevant feature. A 65-year-old 
man was referred to our center to investigate multiple hepatic nodules evidenced by abdominal tomography. He had 
a recent diagnosis of diabetes and complained of significant weight loss (25 kg), crusted skin lesions and episodes of a 
large amount of liquid diarrhea during the past 6 months. On admission, there were erythematous plaques and crusted 
erosions on his face, back and limbs, plus angular cheilitis and atrophic glossitis. The typical skin manifestation promptly 
led dermatologists to suspect glucagonoma as the source of our patient’s symptoms. A contrast-enhanced abdominal 
computed tomography showed a hypervascularized pancreatic lesion and multiple hepatic nodules also hypervascularized 
in the arterial phase. Despite initial improvement of diarrhea after subcutaneous octreotide, the patient’s impaired 
nutritional status limited other therapeutic approaches and he died of respiratory failure due to sepsis. His high levels of 
serum glucagon were not yet available so we performed an autopsy, confirming the diagnosis of metastatic glucagonoma 
with NME on histology. Chronic diarrhea is not a common feature in glucagonoma syndrome; however, its severity can 
lead to serious nutritional impairment and set a poor outcome. 
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INTRODUCTION
The association between skin lesions and multiple 
hepatic nodules has a broad differential diagnosis, 
particularly in patients with chronic diarrhea. It is 
essential to be aware that gastrointestinal tract tumors 
are related to these three conditions, especially gastric, 
colonic and pancreatic tumors.1,2 In this setting, 
feasible hypotheses are hepatic and skin metastases or 
paraneoplastic cutaneous syndromes. Often, despite 
etiological elucidation and treatment, liver spread may 
determine an unfavourable prognosis.3,4
The investigation must be quick. In addition to 
blood tests and serum tumoral markers, upper digestive 
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endoscopy, colonoscopy and contrast-enhanced 
abdominal imaging are essential. Widespread skin 
lesions should not be understood as a finding but as 
part of a systemic disease, so the evaluation of an 
experienced dermatologist is helpful. We report this 
fatal case of an advanced glucagonoma, highlighting 
its severity and systemic involvement.
CASE PRESENTATION
A 65-year-old Caucasian male was referred to 
our tertiary hospital in order to elucidate the etiology 
of multiple hepatic nodules detected by abdominal 
computed tomography (CT). He complained of weight 
loss during the past 6 months (25 kg), non-pruritic skin 
lesions on the face and limbs, weakness, sadness, and 
episodes of a large amount of liquid diarrhea more 
than 20 times a day without blood or mucus. He was 
able to ingest less than one daily meal during the last 
3 months. He was smoker (20 packs-year) and was 
on metformin because of a new-onset diagnosis of 
diabetes mellitus.
On examination the patient had a weakened 
status (body mass index 14 kg/m2), with multiple 
skin lesions (erythematous and brownish plaques 
and crusted erosions) on his face (Figure 1), back 
and limbs. He also had angular cheilitis and atrophic 
glossitis. There were white plaques on the oral mucosa 
suggesting moniliasis. The liver was hardened and 
palpable 4 cm below the costal margin and xiphoid 
process. He had severe asymmetric edema of the lower 
limbs, and there were no palpable lymph nodes.
Labo ra to r y  t e s t s  e v i denced  a  r e l e van t 
normocytic/normochromic anemia with hemoglobin 
3.9 g/dL (reference value [RV] 13-16), low serum 
albumin 1.8 g/dL (RV 3.5-5.2), and low levels of 
calcium, phosphate, magnesium, sodium, zinc, 
folate, and potass ium. Regarding the severe 
anemia, the glycosylated hemoglobin was 5.9% 
(RV 4.0–5.6); the serum C-peptide was unchanged 
(2.7 ng/mL [RV 0.8–4.2]); and the serum insulin 
was low (1.5 UI/mL [RV 3.2–16.3]). Other relevant 
dosages were: prolactin 19 ng/mL (RV 4.0–15.2), 
ferritin 1,872 ng/mL (RV 30–400), with transferrin 
saturation at 88%. The liver enzymes, international 
normalized ratio, bilirubin, parathyroid hormone, and 
adrenocorticotropin were normal. Serum urea and 
creatinine were slightly elevated. Viral hepatitis and 
HIV serologies were negative.
Doppler ultrasonography of the lower limbs 
showed bilateral deep venous thrombosis. Abdominal 
CT evidenced a contrast-enhanced lesion between 
the body and tail of the pancreas measuring 24 mm 
at its largest diameter (Figure 2A). There were also 
multiple hepatic lesions with peripheral enhancement 
in the arterial phase, and a hypodense center, 
suggesting necrosis (Figure 2B). Carbohydrate antigen 
19.9 (CA 19.9) dosage was 413 U/mL (RV < 34); 
other tumoral markers, such as alpha-fetoprotein and 
carcinoembryonic antigen (CEA), were unchanged. The 
stool analysis depicted a fecal osmolar gap of 5.02 
Osm / kg H2O (compatible with secretory diarrhea 
since it is < 50), rare blood red cells, and absence of 
leukocytes, yeasts, fatty acids, helminths and protozoa. 
The patient maintained a high fecal discharge even 
after initial therapeutic measures and parenteral 
nutrition.
An experienced dermatologist evaluated the 
patient. Among the differential diagnosis of cutaneous 
lesions there were pemphigus, malnutrition and 
vitamin deficiencies in the setting of chronic diarrhea. 
However, necrolytic migratory erythema (NME) could 
be a major hypothesis, since it is strongly associated 
with glucagonoma, which could also encompass the 
combination of diabetes mellitus, diarrhea, anemia, 
weight loss and a pancreatic nodule with probable 
liver metastases.
With this in mind, we performed the dosage of 
serum glucagon and vasoactive intestinal peptide (VIP), 
and subsequently initiated subcutaneous octreotide 
Figure 1. Brownish erythematous scaly lesions with 
crusts on the perioral region and nasogenic sulcus.
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100 mcg three times a day. There was satisfactory 
improvement of the diarrhea; however, the patient’s 
condition evolved to septic shock due to pulmonary 
infection, and he died of respiratory failure 20 days 
after admission. The VIP dosage was slightly elevated, 
49.6 pmol/L (RV < 30) and serum glucagon was 
4,354 pg/mL (RV < 208), but we did not yet have this 
dosage on the day he died, so we decided to perform 
the autopsy (with his family’s consent).
AUTOPSY FINDINGS
There were multiple hardened and well-delimited 
nodules in the liver – the largest measuring 85 mm 
(Figure 3A). Between the pancreatic body and tail, 
we found a brownish solid nodule measuring 
28 × 25 × 25mm (Figure 3B) with an enlarged adjacent 
lymph node measuring 20 × 18 × 18 mm.
H i s to log i ca l  ana l y s i s  ev idenced  a  we l l -
differentiated pancreatic neuroendocrine tumor 
(Figure 4A), with lymph node and liver metastases, 
which was confirmed after immunohistochemical 
staining positivity for CD56 (Figure 4B), chromogranin 
A (Figure 4C) and synaptophysin (Figure 4D). 
The proliferating index Ki67 was inconclusive, due 
to autolysis. Skin lesions histology showed epidermis 
with marked degenerative changes and superficial 
necrosis, loss of the granular layer, cytoplasmic 
balloonisation and vacuolisation of keratinocytes, 
which was compatible with NME (Figure 5).
Figure 2. Axial abdominal enhanced CT in the arterial phase showing in A - an enhanced pancreatic nodule 
measuring 24 mm at its largest diameter (white arrow), and multiple hepatic nodules with peripheral enhancement 
and a hypodense center (necrosis); B - multiple hepatic nodules with peripheral enhancement and a hypodense 
center (necrosis).
Figure 3. Macroscopic view of the: A - liver showing multiple hepatic nodules (metastases); B - nodule in the 
pancreatic body (neuroendocrine tumor).
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DISCUSSION
Among the functioning pancreatic neuroendocrine 
tumors, the most common are gastrinomas and 
insulinomas. Glucagonomas are extremely rare, 
with an estimated global incidence of one case in 
20 million people.5,6 The peak presentation is in 
the fifth decade of life, affecting men and women 
in almost equal proportions. Less than 10% of 
tumors are associated with familial syndromes – 
more frequently multiple endocrine neoplasia type 1 
(typically non-functioning).3,7,8 Most are sporadic and 
this presentation has lower survival, since about half of 
the patients have metastases at diagnosis.9,10 Achieving 
effective treatment and reaching higher survival rates 
remain a major issue.
In approximately 87% of cases, sporadic 
glucagonoma is located in the body or tail of the 
pancreas.11 This tumor has an alpha-cell production 
Figure 4. Photomicrographs of the pancreas showing in A - nodular and diffuse infiltration of round cells with 
stippled chromatin, inconspicuous nucleoli, and finely granular cytoplasm (H&E, original magnification × 100); 
B - Immunohistochemical staining positive for CD56 (× 100); C - Immunohistochemical staining positive for 
Chromogranin A (x 100); D - Immunohistochemical staining positive for Synaptophysin (× 100).
Figure 5. Photomicrograph of the skin showing 
spongiosis and parakeratotic hyperkeratosis in the 
upper layer of the epidermis with necrosis, loss 
of the granular layer, vacuolized and dyskeratotic 
keratinocytes, compatible with necrolytic nigratory 
erythema (H&E, original magnification × 20).
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of glucagon,5,12 and the main clinical manifestation is 
known as glucagonoma syndrome (GS). It is a systemic 
condition characterized by the combination of NME, 
high levels of serum glucagon and hyperglycemia.10 
This was our patient’s presentation. There were no 
additional features to suggest multiple endocrine 
neoplasia type 1, except for a slight increase in serum 
prolactin, which was not valued.
NME is a paraneoplastic skin disorder typically 
presented in up to 70%–80% of the patients with GS.10 
Lesions can be widespread but are usually located in 
intertriginous areas, perioral region, perineum, lower 
abdomen, thighs and distal extremities, and may have a 
migratory course, occurring in spontaneous exacerbations 
and remissions. Commonly there are annular or irregular 
eruptions and plaques with superficial epidermal necrosis 
and crusts, leading to pruritus or pain, with susceptibility 
to secondary infection. After lesions heal, residual areas 
of hyperpigmentation and peripheral collarette can 
remain. The most specific histological feature includes 
superficial epithelial necrosis of the upper spinous layer 
with vacuolated keratinocytes.13 Patients may also present 
angular cheilitis, glossitis and alopecia.10 In 90% of 
cases, NME is associated with glucagonoma but some 
conditions – usually leading to nutritional impairment 
– may be involved, such as cirrhosis, cystic fibrosis, 
inflammatory bowel disease, kwashiorkor, celiac disease 
and other neoplasms.7 This rare presentation is known 
as pseudoglucagonoma syndrome.5,14
Other findings of GS include anemia (49.6%), 
we igh t  l o s s  ( 66%–96%) ,  d i a r rhea  ( 30%) , 
abdominal pain (7.5%–10.6%), lower limbs edema, 
venous thromboembolism (50%) and depression 
(50%);3,15-17 these match our patient’s presentation. 
Glucagon-related cardiomyopathy has already been 
described.18 GS is known as 4D syndrome (Dermatosis, 
Diabetes, Deep vein thrombosis and Depression).17 
Diarrhea occurs more frequently in patients with other 
conditions, such as somatostatinomas, gastrinomas, 
VIPomas and carcinoid tumors. Multiple etiologies 
could be associated with that, such as increased 
motility, malabsorption and bacterial overgrowth. 
The consequences are hydroelectrolytic disorders, 
renal disfunction, weight loss and malnutrition.3 This 
was the most relevant symptom in our patient and he 
had also a slightly elevated serum VIP, which may have 
contributed to it.
Glucagonoma is a slowly progressing tumor, and 
some patients develop pancreatic adenocarcinoma 
before the neuroendocrine tumor spreads. Metastases 
are found in half the patients at diagnosis.9,10 and 
occur predominantly in the liver (79%–90%) and 
lymph nodes (30%–37.8%).7 Early recognition of GS 
before liver dissemination can be life-saving,5,19 with 
a 10-year survival reaching 100%.20 However, after 
it spreads to the liver, survival drops by half.17 When 
there is massive hepatic involvement the liver cannot 
properly metabolize glucagon, icreasing its levels and 
thereby worsening the symptoms.17
Song et al.12 evaluated 623 reported cases of 
glucagonoma. The male to female ratio was 0.79 and 
metastases were detected in 49.2% of patients. These 
subjects were older than those without metastases 
upon diagnosis (54.0 vs. 50.8 years old). The average 
time between initial symptoms and diagnosis of the 
tumor was 31.4 months. Wei et al.9 reported six cases 
of GS in a 17-year database. Most were women (4/6), 
and the median age at diagnosis was 48.8 years 
(younger than our patient). NME was found in all 
subjects and was the first symptom in 67%. Five 
patients had diabetes mellitus and the other one 
had impaired glucose tolerance. The whole group 
had anemia, and the serum glucagon ranged from 
245.6 to 1,132.0 pg/mL. The highest value was a 
quarter of our patient’s level.
In a series of 21 patients with GS reported 
by Wermers et al.14, eleven were male (52,4%). 
The median age at diagnosis was 54 years (also 
younger than our patient). Twenty subjects had already 
liver spread at diagnosis and the other one had lymph 
node dissemination. However, just 9/21 patients had 
tumor-related death, which occurred on average 
4.91 years after diagnosis.
Despite the diverse clinical features, the diagnosis 
of glucagonoma requires evidence of a pancreatic 
lesion by an imaging examination. As this tumor 
is often located in the distal pancreas, the role of 
ultrasonography seems to be limited.21 Therefore, 
the most useful methods are contrast-enhanced 
imaging, such as CT and magnetic resonance.5,21 
Positron emission tomography or octreotide scan 
scintigraphy may be applicable especially when there 
is concern for distant disease.22 In addition to the 
dosage of serum glucagon, C-peptide and usual 
laboratory measurements (blood count, lipids, glucose, 
glycosylated hemoglobin, vitamins, electrolytes, iron, 
ferritin, hepatic and renal function), hormonal profile 
must be evaluated, since glucagonomas (as other 
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islet cell neoplasms) may overproduce multiple 
hormones, such as insulin, adrenocorticotropin, 
parathyroid hormone, gastrin and VIP.3,5,17 High 
levels of chromogranin A have been associated with 
advanced disease.23
The management of glucagonomas is wide and 
multifactorial. Hyperglycemia can be controlled using 
insulin or oral blood glucose lowering drugs. Ketoacidosis 
rarely occurs since pancreatic beta cells are preserved. 
Somatostatin analogues (octreotide/lanreotide) have 
effective suppression on glucagon secretion, so it 
is used to improve GS symptoms, such as diarrhea 
and skin lesions.10,24 However, it may work through 
other mechanisms as some cases have had a response 
independent of the decrease in glucagon levels. 
The use of somatostatin analogues is a well-tolerated 
and safe therapy, but it has lower effectiveness in the 
management of diabetes mellitus and does not reduce 
the incidence of venous thrombosis, which requires 
prophylactic low doses of heparin.24
Nutritional support is necessary, since patients 
have usually a relevant weight loss.22 Total parenteral 
nutrition with amino acid and caloric supplementation 
may be used to counteract the catabolic effects of 
high glucagon.19 Surgical resection of the pancreatic 
nodule is indicated whenever possible.25-29 After tumor 
resection, the symptoms of GS commonly decrease.22 
Unfortunately, less than 15% of patients with liver spread 
have the possibility of surgical cure, requiring additional 
therapy.21 Interferon-alpha, everolimus and sunitinib 
are useful, especially in the presence of liver metastases. 
Embolisation, chemoembolisation and radioablation 
may be performed with satisfactory outcomes.2,3,28 
Radioisotope therapy can also benefit some patients.6,30
When patients are not able to undergo surgery, 
systemic chemotherapy can be conducted, particularly 
streptozotocin and doxorubicin.5 Cryoablation is an 
option to treat the pancreatic tumor and NME, but it 
requires additional studies to prove efficacy.10 After 
pancreatic resection, liver transplantation should also 
be considered in cases with clinically controlled disease, 
even in the presence of hepatic metastases.18,31
Our patient was older than most of the previously 
related cases of sporadic glucagonoma. He could not 
undergo surgery because of his impaired nutritional 
status. He had a delayed diagnosis. He was not 
receiving satisfactory nutrition and did not experience 
episodes of hypoglycemia probably because of his very 
high levels of glucagon. When he was finally admitted 
to hospital, the diagnosis was suspected and treatment 
was promptly initiated; however, we were not able 
to prevent his unfavourable but presumed outcome.
CONCLUSION
Dermatosis, Diabetes, Deep vein thrombosis 
and Depression characterize the 4D GS – a main 
manifestation of glucagonomas. Necrolytic migratory 
erythema is the most specific presentation but the 
systemic involvement of this syndrome must be broadly 
recognized. Our intention is not really to change the 
acronym ‘4D’ to ‘5D’, but to emphasize that although 
chronic secretory diarrhea is not such a common clinical 
feature, it leads to severe nutritional impairment and 
can set a poor outcome, especially in elderly patients.
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